LUPINNSELupin Limited· PharmaceuticalsHighPositive
Announced Wed, 14 May · 22:25 IST

Lupin Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Lupin reported strong FY25 results with standalone revenue growing ~15.7% YoY to ₹16,968 crore and net profit surging ~71% to ₹3,973 crore. Q4 standalone revenue rose ~32% to ₹4,486 crore with net profit of ₹1,291 crore (vs ₹384 crore in Q4 FY24). On a consolidated basis, FY25 revenue grew ~13.5% to ₹22,708 crore while PAT jumped ~71% to ₹3,306 crore. Standalone EPS for the year stood at ₹87.10 versus ₹51.10 last year. The Board recommended a dividend of ₹12 per share (600% on face value of ₹2), aggregating to ₹547.9 crore, subject to shareholder approval. The company recorded exceptional items of ₹77.2 crore towards impairment of investments in two subsidiaries and made a ₹85.6 crore provision for an ongoing dispute. Auditors B S R & Co. LLP issued an unmodified opinion on the results.

Likely market impact

Strong double-digit profit growth, expanding margins, and a healthy 600% dividend make this a positive outcome for shareholders. The robust earnings may support positive sentiment, though the new debt raise and provisions for disputes are minor watchpoints.